Share on StockTwits

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ)‘s stock had its “neutral” rating reiterated by Zacks in a report released on Friday. They currently have a $157.00 target price on the stock. Zacks‘s price target points to a potential upside of 4.95% from the stock’s previous close.

Zacks’ analyst wrote, “Jazz’s first-quarter earnings of $1.51 per share were above the year-ago earnings of $1.25 per share. Quarterly revenues increased 26% year over year to $246.9 million. We are encouraged by the strong growth exhibited by key products, Xyrem and Erwinaze. Both should continue performing well. We are also positive on Jazz’s efforts to boost sales through label expansion. The Gentium acquisition also looks good. We believe the company will continue to pursue such deals to boost its product portfolio and pipeline. Meanwhile, the Xyrem patent litigation is a matter of concern. We maintain a Neutral recommendation on the stock.”

JAZZ has been the subject of a number of other recent research reports. Analysts at JMP Securities initiated coverage on shares of Jazz Pharmaceuticals plc – in a research note on Tuesday. They set an “outperform” rating and a $179.00 price target on the stock. Separately, analysts at Wells Fargo & Co. initiated coverage on shares of Jazz Pharmaceuticals plc – in a research note on Tuesday, June 10th. They set an “outperform” rating on the stock. Finally, analysts at Cantor Fitzgerald reiterated a “hold” rating on shares of Jazz Pharmaceuticals plc – in a research note on Tuesday, May 27th. They now have a $151.00 price target on the stock, down previously from $182.00. Five research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Jazz Pharmaceuticals plc – presently has a consensus rating of “Buy” and an average target price of $171.50.

In other Jazz Pharmaceuticals plc – news, EVP Fintan Keegan sold 3,750 shares of the stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $150.00, for a total transaction of $562,500.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded up 2.43% on Friday, hitting $153.22. 486,265 shares of the company’s stock traded hands. Jazz Pharmaceuticals plc – has a 1-year low of $64.75 and a 1-year high of $176.60. The stock has a 50-day moving average of $138.7 and a 200-day moving average of $140.2. The company has a market cap of $9.100 billion and a P/E ratio of 113.76.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last announced its earnings results on Thursday, May 8th. The company reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.79 by $0.18. The company had revenue of $247.00 million for the quarter, compared to the consensus estimate of $254.86 million. During the same quarter in the previous year, the company posted $1.37 earnings per share. The company’s revenue for the quarter was up 25.8% on a year-over-year basis. Analysts expect that Jazz Pharmaceuticals plc – will post $8.07 EPS for the current fiscal year.

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.